Extended Alefacept Treatment for Psoriasis

Title: An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis.
Authors: Gribetz CH, et al.
Publication: J Am Acad Dermatol. 2005 Jul;53(1):73-5.

The efficacy and safety of alefacept in one or two courses (12 weeks each) have been demonstrated in phase 2 and 3 clinical trials. The authors wanted to see compare this with an extended course of 16 weeks alefacept treatment.

To do this, the authors enrolled 20 patients with chronic plaque psoriasis and divided them into 2 groups (12-week and 16-week). They evaluated the treatment progress using PASI (Psoriasis Area and Severity Index) by comparing before and after treatment (with a follow up at week 24).

In both the 12-week and 16-week groups, 60% achieved PASI 50 (reduction of psoriasis severity by half according to PASI scores) any time between weeks 12 and 24. The mean percentage change in PASI from week 12 to week 24 was higher for the those who received alefacept for 16 weeks as compared to those who only received 12 weeks of it.

The authors noted that adverse side effects were similar between the 12-week and 16-week groups. They concluded that in this open-label, single-center study of 20 patients, extending the dose of alefacept to 16 weeks had further benefits with a similar safety profile to 12-week dose.

Main Menu
Health Articles
Health News
Health Research
Site Map

Health Conditions
Cardiovascular Health
Digestive Health
Infectous Diseases
Musculoskeletal Health
Pregnancy & Childbirth
Skin Health

Misc. Health Articles
Presidential Diseases

Medical Research

Psoriasis Overview
Psoriasis Pictures
Research Summaries

©copyright 2004 - Health In Plain English. All Rights Reserved.

Health Articles Health News Health Research Explained in Plain English